SERPINA2 and prostate adenocarcinoma: Initially, we analyzed the genomic alteration profiling of ARGs gene set in PRAD patient samples from the TCGA database, and it was showed that 43% (214/497) of PRAD patient samples had at least one genomic alteration, including missense, splice, truncating, amplification, and/or deep deletion alterations in ARGs (Fig. 2A).